Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis C Treatment Investigation Was Announced

12 September 2017 12:30

Johnson & Johnson with Achillion Pharmaceuticals were down slightly at more than 20 percent in premarket trading after the announcement of Janssen Sciences Ireland about the discontinuation of further development of hepatitis C treatment investigation. The Janssen authorities comment on that it was a strategic decision because of the number of brand new therapy for hepatitis C, and the number increases rapidly.

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists," comment on  Lawrence Blatt, global therapeutic area head, infectious disease therapeutics, Janssen.


Share with Telegram

Latest News

New high-quality pill for HIV to be launched in low-and middle-income countries at reduced price

New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price. For about $75, the governments in South Africa and Kenya will soon be able to treat an HIV-infected person for 1 year with a pill taken ...

22 September 14:27

Marathon training is safe for people with HIV

Marathon run training is safe for people with HIV, investigators from Germany report. Training also had a number of beneficial effects, including a significant increase in CD4 cell count and improvements in cholesterol and blood pressure. «The main finding of our study was ...

21 September 13:44

Sanofi tests three-in-one antibody to treat or prevent HIV

A three-pronged man-made antibody, created by French drugmaker Sanofi and U.S. scientists, could offer a new way to treat or prevent HIV, following successful tests in monkeys. If all goes well, the three-in-one antibody could be used either as a long-acting treatment or ...

21 September 12:28

By 2020, 70% of people living with HIV in the US will be 50 or older

Due to enormous advances in treatment, people are able to live far longer; so much so that by the year 2020, 70 percent of those living with HIV in the US will be over the age of 50. This is good news, but it brings with it unique complexities. Philanthropic funding is a ...

20 September 14:53